SCHEMBL3067153

SCHEMBL3067153

Cc1nc(N(C)C)sc1C(=O)Cl

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.40
HPGD P15428 2/20 0.40
TSHR P16473 1/20 0.40
POLB P06746 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ADORA2A P29274 1/20 0.35
RAB9A P51151 5/20 0.35
NPC1 O15118 4/20 0.35
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 4/20 0.33
GAA P10253 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 2/20 0.33
HTT P42858 1/20 0.32
HTR2C P28335 1/20 0.31
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6761935 0.82 ALDH1A1 (0.55) ALDH1A1HPGDTSHRPOLBADORA2A
SCHEMBL4797009 0.82 RXFP1 (0.45) ALDH1A1HPGDTSHRL3MBTL1RAB9A
Hydrochloric Acid SCHEMBL8552956 0.81 ALDH1A1 (0.53) ALDH1A1HPGDTSHRPOLBADORA2A
Hydrochloric Acid SCHEMBL6113899 0.81 RXFP1 (0.44) ALDH1A1HPGDTSHRL3MBTL1RAB9A
Bromide SCHEMBL6123463 0.81 SMN1; SMN2 (0.44) ALDH1A1HPGDTSHRL3MBTL1RAB9A
SCHEMBL6127601 0.77 ALDH1A1 (0.49) ALDH1A1HPGDTSHRPOLBL3MBTL1
SCHEMBL3344131 0.75 CNR1 (0.47) ALDH1A1HPGDTSHRL3MBTL1RAB9A
SCHEMBL18453337 0.75 ALDH1A1 (0.36) ALDH1A1HPGDTSHRPOLBL3MBTL1
Bromide SCHEMBL6114064 0.75 ALDH1A1 (0.48) ALDH1A1HPGDTSHRPOLBL3MBTL1
SCHEMBL8555889 0.75 ALDH1A1 (0.62) ALDH1A1HPGDTSHRRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541406-B2 Thiadiazole derivatives for the treatment of neurodegenerative diseases NV REMYND (BE) 2013-09-24 US disclosed
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2010-10-14 US disclosed
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-09-17 US disclosed
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-26 US disclosed
EP-0639574-B1 2-aminothiazolecarboxamide derivatives, processes for their preparation and their use for controlling phytopathogenic organisms LUCKY LTD (KR) 1998-06-10 EP disclosed
US-5514643-A FUNGICIDES FOR PLANTS LUCKY LTD. (KR) 1996-05-07 US disclosed
EP-0639574-A1 2-aminothiazolecarboxamide derivatives, processes for their preparation and their use for controlling phytopathogenic organisms LUCKY LTD. (KR) 1995-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 ALDH1A1 1930/4885HPGD 1746/4885TSHR 3338/4885
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 ALDH1A1 1930/4885HPGD 1746/4885TSHR 3338/4885
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 ALDH1A1 1930/4885HPGD 1746/4885TSHR 3338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.